Healthcare marketing.

FDA OPDP for drug promotion. HIPAA and state boards for practice marketing.

Pharmaceutical marketing is governed at the federal level by the Food and Drug Administration, specifically the Office of Prescription Drug Promotion under the Federal Food, Drug, and Cosmetic Act ⁴ . The core requirement is that promotional labeling be truthful, maintain fair balance between risks and benefits, and adhere to FDA-approved indications. When a manufacturer engages in direct-to-consumer advertising the regulatory burden rests on the manufacturer to disclose side effects and contraindications in the ad copy itself. A physician practice marketing its services does not act as a pharmaceutical manufacturer; the FDA framework is largely out of scope for the practice's SEO and digital presence.

What governs the practice instead is HIPAA Privacy Rule at the federal level and the state medical board at the local level. 45 CFR 164.501 defines marketing as a communication about a product or service that encourages recipients to purchase or use it ¹ . 45 CFR 164.508 then sets the per-recipient written-authorization requirement when the communication uses Protected Health Information ² . The authorization names what gets disclosed, who receives it, the purpose, an expiration date, and the patient's revocation rights. The five required elements are the workflow that every patient testimonial, identifiable before-and-after image, and identifiable case study has to clear before reaching a service page.

The 'own products and services' exception under 45 CFR 164.501 carves out practice-announcement communications and treatment-communication contexts from the authorization requirement ¹ . A hospital can use its patient list to announce a new physician arrival or the acquisition of a new MRI machine. Prescription refill reminders and care-coordination referrals are exempt. The exception breaks the moment a third party pays the covered entity to make the communication. A drug manufacturer paying a clinic to send discount coupons triggers the authorization requirement; the same email without the third-party payment does not.

AMA Code of Medical Ethics Opinion E-9.6.1 governs the substance of physician advertising ³ . Advertising must be truthful, must not create unjustified expectations, must not contain false comparative claims, and must not use testimonials that misrepresent typical experience. State medical boards mirror E-9.6.1 and add jurisdictional specificity. The Florida Board of Medicine adds testimonial-typicality language and a retained-consent-period rule. California, Texas, and New York each layer additional rules. Multi-state telehealth practices have to clear the strictest market's bar on the patient-facing surface because AMA Code Opinion 1.2.12 binds the attending physician to active licensure in the state where the patient sits at the moment of consult ⁵ .

Reviews System 2023+ evaluates first-party editorial. ABMS board certification carries the YMYL weight.

Google's Reviews System medical-content framework evaluates first-party standalone editorial content for practicing-physician reviewer signals ⁶ . The framework explicitly does not evaluate third-party patient testimonials. The two surfaces on a medical practice site face different rules. Editorial articles where a physician authors a comparative review of two CPAP machines or evaluates a new laser therapy sit inside the framework; the patient quote on the procedure page does not.

The editorial byline has to surface the author's ABMS board-certification status ⁷ . The American Board of Medical Specialties and its 24 member boards establish the rigorous standards for specialty certification, requiring three to five years of ACGME-accredited residency training and the passing of board-administered examinations. Physicians must maintain the status through the ABMS Maintenance of Certification program. Google's medical-content evaluators weight the credential heavily. A general practitioner authoring complex oncological articles is the documented YMYL-demotion pattern. The byline on Praxis-architected editorial content surfaces ABMS specialty and active state license alignment with the article topic.

The line Praxis holds, repeatedly: the agency is not a medical entity. The agency works the SEO architecture, the schema layer, the editorial framing, and the regulatory boundary. The medical substance is authored or reviewed by credentialed practicing physicians at the practice. The author bylines on the practice's site reflect that. The disclaimer in the practice's footer states it explicitly.

This hub sits inside the broader Medical SEO practice at Praxis. The healthcare-marketing regulatory boundary is the framing; the work that ships against it lives across the Tier 2 services, the schema layer, and the editorial-content architecture.